Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate
Explore this paper's citation graph
Summary
These data indicate that PA and PB penetrate well into the CSF after i.v. administration, and there may be an advantage to administration ofPB over PA, since the administration of PB results in significant exposure to both active compounds.
- Type
- article
- Published
- 2001-05-01
- Cited by
- 33
- References
- 0
- OpenAlex
- https://openalex.org/W1984460399
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32012173
Keywords
Pharmacokinetics, Cerebrospinal fluid, Chemistry, Metabolite, Pharmacology
References
No references recorded for this paper.
Cited by
- Phase 2 study of sodium phenylbutyrate in ALS
- CHARACTERIZATION AND TREATMENT OF A NOVEL MOUSE MODEL OF TSC-ASSOCIATED AUTISM
- Mitochondrial Apoptosis: A New Foundation for Combining Agents in Prostate Cancer Treatment
- Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients
- Clinical and Experimental Applications of Sodium Phenylbutyrate
- Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy
- Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
- Sodium 4-phenylbutyrate protects against spinal cord ischemia by inhibition of endoplasmic reticulum stress.
- Determination of phenylbutyric acid and its metabolite phenylacetic acid in different tissues of mouse by liquid chromatography with tandem mass spectrometry and its application in drug tissue distribution.
- Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model.
- Emerging chemotherapeutic strategies for Huntington’s disease
- Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
- Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse Model
- Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
- Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells.
- Validating a nonhuman primate model of super-selective intraophthalmic artery chemotherapy: comparing ophthalmic artery diameters.
- Epigenetic Mechanisms in Cerebral Ischemia
- Activation of Endoplasmic Reticulum Stress by Hyperglycemia Is Essential for Müller Cell–Derived Inflammatory Cytokine Production in Diabetes
- Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.
- Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy.
Related papers
- L-thyroxine treatment in primary hypothyroidism does not increase the content of free triiodothyronine in cerebrospinal fluid: A pilot study
- The anorectic effect of oestradiol does not involve changes in plasma and cerebrospinal fluid leptin concentrations in the rat.
- Plasma and cerebrospinal fluid leptin levels are maintained despite enhanced food intake in progesterone-treated rats.
- Plasma and cerebrospinal fluid alpha-MSH levels in the rat after hypophysectomy and stimulation of pituitary alpha-MSH secretion.
- Oral, Intraperitoneal and Intravenous Pharmacokinetics of Deramciclane and its N‐desmethyl Metabolite in the Rat
- Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
- The multiple-dosing pharmacokinetics of artemether, artesunate, and their metabolite dihydroartemisinin in rats
- Pharmacokinetics of dolasetron following single‐ and multiple‐dose intravenous administration to normal male subjects
- In Vitro–In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of Its Metabolite
- Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.